Bharat Immunologicals & Biologicals Corporation Limited reported earnings results for the first quarter ended June 30, 2023. For the first quarter, the company reported revenue was INR 1.02 million compared to INR 106.23 million a year ago. Net loss was INR 45.87 million compared to INR 49.97 million a year ago.

Basic loss per share from continuing operations was INR 1.06 compared to INR 1.16 a year ago. Diluted loss per share from continuing operations was INR 1.06 compared to INR 1.16 a year ago.